These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7237468)

  • 61. Enzymic coupling of catharanthine and vindoline to form 3',4'-anhydrovinblastine by horseradish peroxidase.
    Goodbody AE; Endo T; Vukovic J; Kutney JP; Choi LS; Misawa M
    Planta Med; 1988 Apr; 54(2):136-40. PubMed ID: 3406173
    [No Abstract]   [Full Text] [Related]  

  • 62. Gas chromatographic-mass spectrometric analysis of major indole alkaloids of Catharanthus roseus.
    Ylinen M; Suhonen P; Naaranlahti T; Lapinjoki SP; Huhtikangas A
    J Chromatogr; 1990 May; 505(2):429-34. PubMed ID: 2355069
    [No Abstract]   [Full Text] [Related]  

  • 63. Vinca alkaloids in the treatment of non-small cell lung cancer.
    Sørensen JB; Osterlind K; Hansen HH
    Cancer Treat Rev; 1987 Mar; 14(1):29-51. PubMed ID: 3036349
    [No Abstract]   [Full Text] [Related]  

  • 64. Radioimmunoassay for the quantitative determination of catharanthine.
    Deus-Neumann B; Stöckigt J; Zenk MH
    Planta Med; 1987 Apr; 53(2):184-8. PubMed ID: 3602145
    [No Abstract]   [Full Text] [Related]  

  • 65. [Assay by densitometry of alkaloidic impurities in the vincristine sulfate (author's transl)].
    Panas JM; Etcheverry MF; Yzerman JM; Ledouble G
    Ann Pharm Fr; 1979; 37(1-2):49-54. PubMed ID: 496221
    [No Abstract]   [Full Text] [Related]  

  • 66. Catharanthus roseus L. plants and explants infected with phytoplasmas: alkaloid production and structural observations.
    Favali MA; Musetti R; Benvenuti S; Bianchi A; Pressacco L
    Protoplasma; 2004 Mar; 223(1):45-51. PubMed ID: 15004742
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics and metabolism of vinblastine in humans.
    Owellen RJ; Hartke CA; Hains FO
    Cancer Res; 1977 Aug; 37(8 Pt 1):2597-602. PubMed ID: 889590
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Analytical limits in clinical pharmacokinetics: example of vinca-alkaloids].
    Solere P; Lucas C
    Bull Cancer; 1991; 78(9):775-87. PubMed ID: 1751829
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Clinical pharmacokinetics of vinca alkaloids].
    Rahmani R; Samak R; Bore P; Cano JP
    Bull Cancer; 1988; 75(2):195-200. PubMed ID: 3359064
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
    Gan PP; Kavallaris M
    Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-performance liquid chromatographic and TLC determinations of desacetylvinblastine amide (vindesine) and its monosulfate salt.
    Hussey RL; Newlon WM
    J Pharm Sci; 1978 Sep; 67(9):1319-20. PubMed ID: 690842
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).
    Dyke RW; Nelson RL
    Cancer Treat Rev; 1977 Jun; 4(2):135-42. PubMed ID: 329987
    [No Abstract]   [Full Text] [Related]  

  • 73. Energetics of vinca alkaloid interactions with tubulin.
    Lobert S; Correia JJ
    Methods Enzymol; 2000; 323():77-103. PubMed ID: 10944748
    [No Abstract]   [Full Text] [Related]  

  • 74. Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors.
    Miller TP; Jones SE; Chester A
    Cancer Treat Rep; 1980; 64(8-9):1001-3. PubMed ID: 7448818
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential strategies for circumventing myeloperoxidase-catalyzed degradation of vinca alkaloids.
    Schlaifer D; Cooper MR; Attal M; Rousseau A; Pris J; Laurent G; Myers CE
    Leukemia; 1994 Apr; 8(4):668-71. PubMed ID: 8152263
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Determination of vinca alkaloids in plasma and urine using ion-exchange chromatography on silica gel and fluorescence detection.
    Vendrig DE; Teeuwsen J; Holthuis JJ
    J Chromatogr; 1988 Dec; 434(1):145-55. PubMed ID: 2854133
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vitro sensitivity of normal granulocytic and lymphoma colonies to vinca alkaloids.
    Smith SD; Trueworthy RC; Kisker SE; Noller LG; Lowman JT
    Cancer; 1983 Feb; 51(3):417-22. PubMed ID: 6600412
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [The combination therapy with vinca-alkaloid slow infusion and cholchicine was effective to refractory idiopathic thrombocytopenic purpura. The patient could receive femoral head replacement in safety].
    Nezu M; Oh H; Cho R; Sato H; Ikegami T; Yokota A; Nakaseko C; Nishimura M; Matsuura Y; Morio S; Hiruma K; Nakamura H; Asai T
    Rinsho Ketsueki; 1996 Feb; 37(2):158-60. PubMed ID: 8852035
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
    Ono M; Tanaka N
    In Vivo; 1997; 11(3):233-41. PubMed ID: 9239517
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature.
    Van Tellingen O; Beijnen JH; Nooyen WJ
    J Pharm Biomed Anal; 1991; 9(10-12):1077-82. PubMed ID: 1822176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.